

Outreach Beyond Primary Care: Educating Dentists on Opioid Safety in Utah

Adrienne E. Butterwick, MPH, CHES

Manager, Patient Safety Comagine Health Salt Lake City, Utah

Disclosure Statement

I do not have any relevant financial/non-financial relationships to disclose

What types of health care professionals have you detailed outside of primary care clinicians?

Start the presentation to see live content. For screen share software, share the entire screen. Get help at pollev.com/app


Qualis Health & HealthInsight have joined forces to do great things.

Comagine Health

Together, we're reimagining health care.



Number of accidental and undetermined drug deaths by drug type, All ages, Utah, 2000-2019*



Training Curriculum – Best Practices for Safe Prescribing

- "Hybrid" Academic Detailing model whole team education
- Access PDMP prior to prescribing, access data on prescribing
- Reduce # opioid pills prescribed for acute conditions (when appropriate)
- Increase use of Naloxone Overdose Reversal Kits
- **Recognize** abuse/addiction/dependence and **intervene**
- Ensure all patients that are prescribed controlled substances are **safe**

Timeline

Sept. 2018 – April 2019: Developed program based on adapted model of academic detailing specific to Utah prescribers.

May 2019 – Aug. 2019: Phase 1 trainings for medical and dental providers, focused on Carbon County and individual/independent practices along the Wasatch front.

Feb. 2020 – Sept. 2020: Phase 2 trainings for medical and dental providers, expanded to large clinical groups



Search Criteri Date Range: 09/12 Last Name: PAP					Active Dispensing Reco	rds Total Active Daily Morphine Milligram Equivalents (MME) 150	Home C # Prescribers in 6 Months 3 A	Contact Us # Pharmacies in 6 Months 1 ¢	Active Benzos and Opioids NO
Show 10 ♦ entr First Name ♦	ies Last Name ≑	Drug	Quantity 🛊	Date Sold 🔻	Days Supply 🌲	Prescriber Name	S External Re	earch:	ive 🔶 MME 🌲
QUEBEC	PAPA	FENTANYL 25MCG/HR TRANSDERMAL SYSTEM	10	09/10/2018	2	PRESCRIBER TEST RECORD	0	Ye	es 60
QUEBEC	PAPA	OXYCODONE HCL 10MG	10	09/10/2018	2	PRACTITIONER TEST RECORD	0	Ye	es 75
QUEBEC	PAPA	OXYCODONE HCL 10MG	30	09/10/2018	30	TESTER, TEST MD	0	Ye	es 15
Showing 1 to 3 of	3 entries	Back	Search Aga	ain Detai	led Report	Summary		Previous	1 Next

Information contained in this website is protected under Utah Code 58-37f-301, 302, and 601. Unlawful access to or release of database information may subject an individual to felony and misdemeanor criminal liability and a civil penalty of up to \$5,000 per violation.

The information contained in this database is received directly from personnel of the dispensing pharmacy. While efforts are made by pharmacy personnel to ensure accuracy of information provided, DOPL cannot guarantee that all information contained in the database is entirely accurate in every instance.

© 2018 Utah Department of Commerce

1.4.3-6-gad18300

Results



Phase 1 Participant Demographics


Prescriber Demographics (n=46)						
	n	%				
Gender						
Male	35	76.10%				
Female	9	19.60%				
No Answer	2	4.30%				
Race						
Non-White	7	15.22%				
White	39	84.78%				
Specialty						
Dental	28	60.89%				
Medical	18	39.11%				
Average Years Licensed	14.8 years					

Phase 2 Study Participants


Prescribing Dentists (DDS), n = 54 Prescribing Doctors (MD, DO), n = 55 Prescribing Other staff (NP, PA), n = 15

Demographics	Providers who completed a follow up survey (n=87)
Mean years of age (SD)	46.6 (11.2)
Mean practice years (SD)	12.6 (9.9)
% Male	64.3%
% Hispanic	4.9%
% White	81.6%

Number of Opioid Prescriptions with MME >50 Among Participating Providers





Number of Opioid Prescriptions with MME >90 Among Participating Providers



•••••• Linear (Number Prescriptions >90 MME Post)

Number of CSD Queries By Participating Providers and their Delegates/Proxies





Provider Self-report Results Summary (Phase 1)

- •9.1 % increase in self-reported co-prescribing of naloxone
- 20% increase in providers indicating they have an office process in place to check the CSD when prescribing opioids

Areas also positively impacted (large effect size):

- Provider's confidence using the CSD to monitor opioid prescriptions
- Provider knowledge regarding where to refer patients for help with prescription opioid misuse

Provider Self-report Results Summary (Phase 2)

Greatest improvements post training and sustained at 60 days

- Access to screening tools to assess prescription opioid misuse
- Knowledge regarding how to identify patients who misuse prescription opioids
- Knowledge regarding where to refer patients for help for prescription opioid misuse

Medium effects

- More confident using the CSD to monitor opioid prescriptions and this sustained at 60 days
- Have a specific office process in place to check the CSD
- Ratings for the convenience of using the CSD

Looking Ahead

• Shifting focus to surgical academic detailing

- Managing Opioid Use Disorder in the Emergency Department and other settings
- Medications for Opioid Use Disorder Project Extension for Community Healthcare Outcomes (ECHO)

 Safe Opioid Stewardship for Long Term and Post Acute Care Settings

Thank You!

Adrienne E. Butterwick, MPH, CHES Office: 801-892-6646 AButterwick@comagine.org